Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

New Anticancer Therapy to Target Cancer Cells' Elevated Need for Heme

By BiotechDaily International staff writers
Posted on 04 Jul 2013
Image: Space-filling model of heme (Photo courtesy of Wikimedia Commons).
Image: Space-filling model of heme (Photo courtesy of Wikimedia Commons).
Cancer cells have metabolic requirements that separate them from normal cells, and render them vulnerable to drugs that target these processes.

A recent study aimed to identify bioenergetic alterations in lung cancer cells by directly measuring and comparing key metabolic activities in a pair of cell lines representing normal and non-small-cell lung cancer (NSCLC) cells developed from the same patient. Lung cancer is the leading cause of cancer-related mortality in the US and worldwide and about 85% of the cases are NSCLC.

Investigators at the University of Texas (Dallas, USA) worked with a pair of cell lines representing normal nonmalignant HBEC (HBEC30KT) and NSCLC (HCC4017) cells developed from the same patient. They compared the metabolic and molecular profiles of this matched pair of cell lines grown under identical conditions.

Results published in the May 21, 2013, online edition of the journal PLOS ONE revealed that the rates of oxygen consumption and heme biosynthesis were intensified in NSCLC cells. Additionally, the NSCLC cells exhibited substantially increased levels of an array of proteins promoting heme synthesis, uptake, and function. The levels of oxygen-utilizing hemoproteins, such as cytoglobin, were dramatically increased in the cancer cells.

Inhibition of heme with succinyl acetone, a chemical that prevents cells from synthesizing heme, suppressed oxygen consumption, cancer cell proliferation, colony formation, and migration.

"Cancer cells not only make significantly more heme, we also found they uptake more heme from the blood," said senior author Dr. Li Zhang, professor of molecular and cell biology at the University of Texas. "All cells need a certain level of heme, but our findings indicate that normal cells need much less heme compared to cancer cells. We think a high level of heme in cancer cells results in a lot more hemoproteins, which metabolize oxygen and produce more cellular energy. That then drives the cancer cells to proliferate, to migrate, and to form colonies."

"When you inhibit heme synthesis or deplete heme, it does not affect normal cells too much," said Dr. Zhang. "It selectively affects cancer cells. That is the beauty of our work. Because inhibiting heme effectively arrested the progression of lung cancer cells, our findings could positively impact research on lung cancer biology and therapeutics."

Related Links:

University of Texas





comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.